NCT06030089View on ClinicalTrials.gov

Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven

NAActive, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

October 15, 2025

Conditions
Acute Myeloid Leukemia
Interventions
OTHER

Pharmacokinetic sampling

4 blood withdrawals ( before treatment, Day 5, Day 9 and relapse or 12 months after start of treatment) for the plasma dosage of VEN and inhibition of its Bcl-2

OTHER

Vital status determination

Survival situation 12 months after start of treament

OTHER

Toxicity assessments

Toxicity events

DRUG

Venetoclax and azacitidine combination

Response to treatment

Trial Locations (2)

Unknown

Hopital la Conception, Marseille

CHU de Nice, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER